Voriconazole 200mg powder and solvent for solution for infusion vials
Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections.[L15571] It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised.
Genetic variations that may affect drug response
3 known genetic variations may influence how your body responds to Voriconazole 200mg powder and solvent for solution for infusion vials.Gene involved: CYP2C19
These are known genetic variations. They don't mean the medicine won't work for you — speak to your doctor or a pharmacogenomics specialist for personalised advice. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Voriconazole
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Voriconazole
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
400 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(1)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 18 · Randomised trials: 10 · 2001–2026
Showing the 50 most relevant studies, sorted by most relevant.
Me‐Linh Luong, Mona Al-Dabbagh, Andreas H. Groll, et al.
Journal of Antimicrobial Chemotherapy, 2016
Haiying Jin, Tiansheng Wang, Bonnie Falcione, et al.
Journal of Antimicrobial Chemotherapy, 2016
- Invasive Fungal Infections
- Antifungal Agents
- Liver
Johan Maertens, Galia Rahav, Dong‐Gun Lee, et al.
The Lancet, 2021
- Antifungal Agents
- Triazoles
Johan Maertens, Issam Raad, Kieren A. Marr, et al.
The Lancet, 2015
- Antifungal Agents
- Aspergillosis
- Injections, Intravenous
B-J Kullberg, JD Sobel, Markus Ruhnke, et al.
The Lancet, 2005
- Amphotericin B
- Antifungal Agents
- Candidiasis
John R. Wingard, Shelly L. Carter, Thomas J. Walsh, et al.
Blood, 2010
- Antifungal Agents
- Aspergillosis
- Galactose
Wan Beom Park, Nak‐Hyun Kim, Nak‐Hyun Kim, et al.
Clinical Infectious Diseases, 2012
- Antifungal Agents
- Aryl Hydrocarbon Hydroxylases
- Aspergillosis
R. Ally, Dirk Schürmann, Wolfgang Kreisel, et al.
Clinical Infectious Diseases, 2001
- Antifungal Agents
- Candidiasis
- Consumer Product Safety
Xiaofei Li, Caiyuan Yu, Tiansheng Wang, et al.
European Journal of Clinical Pharmacology, 2016
Huilin Tang, Weilong Shi, Yiqing Song, et al.
Journal of the American Academy of Dermatology, 2019
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
1 found
Half-life
Not available
Mechanism
Voriconazole is used to treat fungal infections caused by a variety of organisms but including Aspergillus spp.
Food interactions
1 warning
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
96%
[L9821]…
Half-life
[L9821]
Protein binding
58%
[L9821]
Volume of distribution
4.6 L/kg
[L9821]…
Metabolism
72%
Elimination
2%
[L9821]
Clearance
5.25-7 L/h
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Voriconazole was approved by the FDA under the trade name Vfend on May 24, 2002.[L34660]
[L9821][L15571]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1386 interactions
[L9821][L15571]
In case of overdose, supportive care and ECG monitoring are recommended. Activated charcoal may aid in the removal of unabsorbed drug. Voriconazole is cleared by hemodialysis at a rate of 121 mL/min which may be helpful in removing absorbed drug.
Carcinogenicity studies found hepatocellular adenomas in female rats at doses of 50 mg/kg and hepatocellular carcinomas found in male rats at doses of 6 and 50 mg/kg. These doses are equivalent to 0.2 and 1.6 times the recommended maintenance dose (RMD). Studies in mice detected hepatocellular carcinomas in males at doses of 100 mg/kg or 1.4 times the RMD.
Hepatocellular adenomas were detected in both male and female mice.
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L9821]
Population pharmacokinetic studies report a reduced bioavailability pediatric patients with a mean of 61.8% (range 44.6–64.5%) thought to be due to differences in first-pass metabolism or due to differences in diet .
[A227613]
Of note, transplant patients also have reduced bioavailability but this is known to increase with time after transplantation and may be due in part to gastrointestinal upset from surgery and some transplant medications. Tmax is 1-2 hours with oral administration. When administered with a high-fat meal Cmax decreases by 34% and AUC by 24%. pH does not have an effect on absorption of voriconazole.
Differences in Cmax and AUC have been observed between healthy adult males and females with Cmax increasing by 83% and AUC by 113% although this has not been observed to significantly impact medication safety profiles.
[L9821]
[L9821]
[L9821]
Population pharmacokinetic studies estimate the median volume of distribution to be 77.6 L with the central compartment estimated at 1.07 L/kg [A227613] Voriconazole is known to achieve therapeutic concentrations in many tissues including the brain, lungs, liver, spleen, kidneys, and heart.
[A38618]
Voriconazole N-oxide is the major circulating metabolite, accounting for 72% of radiolabeled metabolites found.
[L9821]
CYP3A4 contributes to N-oxidation with a Km of 16 μM and Vmax of 0.05 nmol/min/nmol CYP3A4 as well as 4-hydroxylation with a Km of 11 μM and a Vmax of 0.10 nmol/min/nmol CYP3A4.
[A38618]
CYP3A5 and CYP3A7 provide minor contributions to N-oxidation and 4-hydroxylation. The N-oxide and 4-hydroxylated metabolites undergo glucuronidation and are excreted through the urine with other minor glucuronidated metabolites.
[A19483]
[L9821]
[A227613][A187880]
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC J02AC03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Voriconazole
Additional database identifiers
Drugs Product Database (DPD)
13348
ChemSpider
64684
BindingDB
50333117
PDB
VOR
ZINC
ZINC000000014864
GenBank Gene Database
X13296
GenBank Protein Database
578119
UniProt Accession
CP51_CANAL
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3769
GeneCards
FMO1
GenBank Gene Database
M64082
GenBank Protein Database
182671
UniProt Accession
FMO1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3771
GeneCards
FMO3
GenBank Gene Database
M83772
GenBank Protein Database
188631
UniProt Accession
FMO3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2640
GeneCards
CYP3A7
GenBank Gene Database
D00408
GenBank Protein Database
220149
UniProt Accession
CP3A7_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2615
GeneCards
CYP2B6
GenBank Gene Database
M29874
GenBank Protein Database
181296
Guide to Pharmacology
1324
UniProt Accession
CP2B6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9604
GenAtlas
PTGS1
GeneCards
PTGS1
GenBank Gene Database
M31822
GenBank Protein Database
387018
Guide to Pharmacology
1375
UniProt Accession
PGH1_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q412236), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.